Intervention not reported
Overall five year survival ‐ Colorectal cancer · Patients with outcomes after colorectal cancer surgery
It is very uncertain whether the intervention changes overall five year survival ‐ Colorectal cancer (very low certainty).
1 finding from 1 review
Intervention not reported
Overall five year survival ‐ Colorectal cancer · Patients with outcomes after colorectal cancer surgery
The intervention may leads to lower overall five year survival ‐ Colorectal cancer (low certainty).
1 finding from 1 review
Intervention not reported
Overall five year survival ‐ Colorectal cancer · Patients with outcomes after colorectal cancer surgery
The intervention may leads to lower overall five year survival ‐ Colorectal cancer (low certainty).
1 finding from 1 review
Overall survival by type of data ‐ Aggregated data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by type of data ‐ Aggregated data compared with primary surgery (moderate certainty).
1 finding from 1 review
Overall survival by type of data ‐ Individual patient data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by type of data ‐ Individual patient data compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy compared with primary surgery (moderate certainty).
1 finding from 1 review
Overall survival
Hormone replacement therapy (HRT) may leads to lower overall survival compared with no HRT (low certainty).
1 finding from 1 review
Overall survival (5‐year) · women (18 years and older) diagnosed with stage IB2 cervical cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Overall survival (3 years) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Time to mortality (overall survival) · people with liver metastases
It is very uncertain whether microwave coagulation changes time to mortality (overall survival) compared with conventional surgery (very low certainty).
1 finding from 1 review
Intervention not reported
Overall 5‐year survival1 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1008 participants
High
Intervention not reported
Overall Survival (median · Patients with brain metastases
The intervention showed no clear difference in overall Survival (median (low certainty).
1 finding from 1 review
Intervention not reported
Overall 10‐year3 survival · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after PDS
Small‐volume residual disease (SVRD) < 1 cm probably leads to higher overall survival: Median length of compared with NMRD (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether residual disease (RD) > 0 cm changes overall survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced ovarian cancer after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).
1 finding from 1 review